Start the conversation
Shares of Belgian biotech Galapagos NV (Nasdaq: GLPG) were down 26% on Friday after Big Pharma player AbbVie Inc. (NYSE: ABBV) opted out of a rheumatoid arthritis (RA) drug partnership to focus on similar drug of its own.
Both AbbVie and Galapagos are Private Briefing recommendations: We've realized peak gains of more than 100% on AbbVie and more than 663% on Galapagos.
In concert with other biotechs, Galapagos has experienced a hefty sell-off of late: However, even with Friday's freefall we still have a gain of nearly 430%.
Let's take a look at the announcement, what it means and what to expect from here... with both these stocks.Full Story
This is premium content for Private Briefing subscribers only.